MM-082 Addition of Daratumumab to Drug Regimens in the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Aiman, Wajeeha; Anwar, Ayesha; Satti, Danish Iltaf; Hamza, Mohammad; Perez, Alynna Mariz; Khan, Arslan Ahmad; Nepal, Ashish; Supraja, A.; Yeesau, Mariam; Nanjundaiah, Nikhilesh; Kaleem, Muhammad Shaarif; Avula, Sreekant; Dewan, Sandesh; Kosach, Sviatoslav; Tarrar, Talha Azam; Suleman, Muhammad; Ali, Muhammad Ashar

doi:10.1016/s2152-2650(22)01589-0

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, daratumumab-dexamethasone triplet regimens that include either lenalidomide or bortezomib are primary recommendations in cases of refractory and/or relapsed multiple myeloma (RRMM). A number of network meta-analytic studies of random-controlled trials may be cited as recent examples that serve to support the application of daratumumab as a major player in a number of myeloma-based settings [14][15][16][17][18]. Moreover, a subcutaneous formulation of daratumumab/hyaluronidase has recently become available.…”

Section: Monoclonal Antibodies Targeting Cd38mentioning

confidence: 99%

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

Abramson

2023

IJMS

View full text Add to dashboard Cite

The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic shift since the dawn of the current century. This has been driven largely by the introduction of new classes of small molecules, such as proteasome blockers (e.g., bortezomib) and immunomodulators (e.g., lenalidomide), as well as by immunotherapeutic agents starting with the anti-CD38 monoclonal antibody daratumumab in 2015. Recently, other immunotherapies have been added to the armamentarium of drugs available to fight this malignancy. These include the bispecifics teclistamab, talquetamab, and elranatamab, and the chimeric antigen receptor (CAR) T-cell products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). While the accumulated benefits of these newer agents have resulted in a more than doubling of the disease’s five-year survival rate to nearly 60% and improved quality of life, the disease remains incurable, as patients become refractory to the drugs and experience relapse. This review covers the current scope of antimyeloma immunotherapeutic agents, both those in clinical use and in development. Included in the discussion are additional monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bi- and multitargeted mAbs, and CAR T-cells and emerging natural killer (NK) cells, including products intended for “off-the-shelf” (allogeneic) applications. Emphasis is placed on the benefits of each along with the challenges that need to be surmounted if MM is to be cured.

show abstract

Section: Monoclonal Antibodies Targeting Cd38mentioning

confidence: 99%

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

Abramson

2023

IJMS

View full text Add to dashboard Cite

show abstract

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

Abramson

2023

Preprint

View full text Add to dashboard Cite

The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic shift since the dawn of the current century. This has been driven largely by the introduction of new classes of small molecules, such as proteasome blockers (e.g., bortezomib) and immunomodulators (e.g., lenalidomide), as well as by immunotherapeutic agents starting with the anti-CD38 monoclonal antibody daratumumab in 2015. Recently, other immunotherapies have been added to the armamentarium of drugs available to fight this malignancy. These include the bispecifics teclistamab, talquetamab, and elranatamab, and the chimeric antigen receptor (CAR) T-cell products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). While the accumulated benefits of these newer agents have resulted in a more than doubling of the disease’s five-year survival rate to nearly 60% and improved quality of life, the disease remains incurable, as patients become refractory to the drugs and experience relapse. This review covers the current scope of anti-myeloma immunotherapeutic agents, both those in clinical use and in development. Included in the discussion are additional monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), bi- and multi-targeted mAbs, and CAR T-cells and emerging natural killer (NK) cells, including products intended for “off-the-shelf” (allogeneic) applications. Emphasis is placed on the benefits of each along with the challenges that need to be surmounted if MM is to be cured.

show abstract

MM-082 Addition of Daratumumab to Drug Regimens in the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Cited by 2 publications

References 0 publications

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

Contact Info

Product

Resources

About